article thumbnail

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

LifeProNow

January 30, 2025: “The U.S. The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Journavx is contraindicated for concomitant use with strong CYP3A inhibitors.

article thumbnail

Drug Allergy

RX Note

A person who takes a certain drug may experience rashes, while another person who takes the same drug may not have any adverse reactions. Collectively, drug allergy, intolerance and nonimmune drug hypersensitivity reactions have been estimated to comprise 25% of all adverse drug events.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moderna flu vaccine shows superior results in phase 3 study

Pharma Times

Most adverse reactions were mild, with injection site pain the most common local effect. Fatigue, headache and myalgia were the most reported systemic reactions. There were no notable differences between groups in terms of unsolicited or serious adverse events. Safety results were consistent with earlier phase 3 data.

article thumbnail

Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia

Pharmacy Times

Common adverse reactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated. In pediatric patients with persistent or chronic ITP, the most common adverse reactions (10% or more) included viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.

article thumbnail

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025. Accessed July 21, 2025. Accessed July 21, 2025. Accessed July 21, 2025. European Medicines Agency. link] NHS England.

article thumbnail

Medication Counselling

RX Note

Garis Panduan Kaunseling Ubat-ubatan, 2025 The Garis Panduan Kaunseling Ubat-ubatan 2025 is a comprehensive and structured reference guide designed to support the more effective implementation of medication counselling services.

article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. The CRL was received after OLC’s initial Prescription Drug User Fee Act date of June 28, 2025, and cited for deficiencies that are unrelated to OLC itself. June 30, 2025. News release.